Theralase Technologies Inc. (TLTFF: OTCQB) | Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting
Theralase® Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF) has announced:
- Their interim clinical data has been selected for presentation at the American Urological Association (AUA) Annual Meeting in Las Vegas, April 26-29, 2025.
- The presentation titled “Interim Analysis of Light-Activated TLD-1433 in a Phase II Clinical Study of BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ” will be given by Dr. Girish Kulkarni.
- The data shows high safety and efficacy of the treatment, with some patients demonstrating a duration of response of 3 years or more with a single treatment.
- The company’s drug, Ruvidar™ (TLD-1433), is designed to treat BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) Carcinoma In-Situ (CIS).
- Patient enrollment for the study is scheduled to be completed in 2025, with clinical data submission to Health Canada and the FDA in 2026.
- Pending regulatory approval, Theralase® plans to make this technology commercially available to urologists in 2027.
- The company is also planning to evaluate Ruvidar™ for other cancers in 2025, including brain, lung, pancreatic, and muscle invasive bladder cancer.
This announcement highlights Theralase’s progress in developing a potentially significant new treatment for bladder cancer.
PressAlchemy helps businesses of all size from startups to established companies to turn their news into headlines. Whether you’re announcing a corporate update, sharing a major project milestone, or launching a new product, press release distribution ensures your story reaches the right audience on top platforms. If you own a business or have a story to share, now’s the time to get noticed.
Expand your reach to 900+ Media Networks, 13.3k Journalists, and a global audience of over a billion users! Get your Press Release or Article featured for your business or story – CLICK HERE.
#Theralase #Technologies #TLTFF #OTCQB #TheralaseR #Interim #Clinical #Data #Presented #AUA #Annual #Meeting
